Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Acq. announced
|
|
ASSEMBLY BIOSCIENCES, INC. (ASMB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AMENDMENT NO. 6 TO ASSEMBLY BIOSCIENCES, INC. 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation adopted the 2018 Stock Incentive Plan on May 30, 2018, which was amended by Amendment No. 1 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan effective as of May 17, 2019, by Omnibus Amendment to Assembly Biosciences, Inc. Stock Plans effective as of March 11, 2020, by Amendment No. 3 effective as of June 11, 2020, by Amendment No. 4 effective as of May 20, 2021 and Amendment No. 5 effective as of May 25, 2022 . Prior to this Amendment No. 6 to the Plan, the number of shares of Common Stock, par value $0.001 per share, reserved under the Plan was 8,600,000. The Board of Directors of the Company may, with stockholder approval, amend the Plan to increase the number..." |
|
| 05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/22/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results|
Docs:
|
"ASSEMBLY BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEETS December 30, December 31, 2022 2021 ASSETS Current assets Cash and cash equivalents $ 52,418 $ 45,627 Marketable securities - short-term 39,192 101,000 Accounts receivable from collaborations 944 336 Prepaid expenses and other current assets 4,413 7,241 Total current assets 96,967 154,204 Marketable securities - long-term — 27,972 Property and equipment, net 743 1,139 Operating lease right-of-use assets 3,195 6,042 Other assets 889 1,703 Total assets $ 101,794 $ 191,060 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 2,493 $ 2,659 Accrued research and development expenses 3,122 3,400 Other accrued expenses 7,317 6,863 Operating lease liabilities - short-term 3,364 3,151 Total current liabilities 16,296 16,07..." |
|
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results|
Docs:
|
"ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2022 2021 ASSETS Current assets Cash and cash equivalents $ 54,673 $ 45,627 Marketable securities - short-term 53,978 101,000 Accounts receivable from collaborations 1,246 336 Prepaid expenses and other current assets 5,181 7,241 Total current assets 115,078 154,204 Marketable securities - long-term — 27,972 Property and equipment, net 867 1,139 Operating lease right-of-use assets 3,958 6,042 Other assets 1,613 1,703 Total assets $ 121,516 $ 191,060 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,942 $ 2,659 Accrued research and development expenses 4,462 3,400 Other accrued expenses 5,686 6,863 Operating lease liabilities - short-term 3,371 3,151 Total current liabilit..." |
|
| 10/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board SOUTH SAN FRANCISCO, Calif., October 5, 2022 – Assembly Biosciences, Inc. , a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced that John G. McHutchison, AO, MD, chief executive officer , will retire as CEO at the end of 2022. Dr. McHutchison will continue to serve on Assembly Bio’s Board of Directors, including assuming the role of chairman of the Science and Technology Committee. Assembly Bio’s Board of Di..." |
|
| 08/09/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/20/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
|
|
|